This is a preview of subscription content, log in via an institution to check access.
Literatur
Baumann M, Herrmann Th, Matthiessen W, Koch R, Strelocke K, Paul U. CHARTWEL-Bronchus (ARO 97-1). Eine randomisiert-multizentrische Studie zum Vergleich einer konventionell fraktionierten Strahlentherapie mit CHARTWEL-Bestrahlung bei inoperablen nichtkleinzelligen Bronchialkarzinomen. Strahlenther Onkol 1997;173:663–7.
Beck-Bornholdt H-P, Dubben H-H, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol 1997;43:1–21.
Dubben H-H, Beck-Bornholdt H-P. Tumorvolumen: ein einfacher und wichtiger Parameter der Strahlentherapie. Exp Strahlenther Klin Strahlenbiol 1997;6:150–4.
Dubben H-H, Beck-Bornholdt H-P. An obvious and underestimated predictive assay: precise, cheap and easy prediction of radiotherapy outcome using tumour volume. Eur J Cancer 1997;33:(Suppl 8):S97–8.
Overgaard J, Bartelink H. About tolerance and quality. An important notice to all radiation oncologists. Radiother Oncol 1995;35:1–3.
Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomized multicentre trial. Lancet 1997;350:161–5.
Shaw E. Looking through the retrospectoscope in the era of evidence-based medicine. J Clin Oncol 1997;15:1289–90; Siehe auch: European School of Oncology, 1996. Internet Adresse: http://www.oncoweb.com/START/
Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259–67.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beck-Bornholdt, H.P., Dubben, H.H., Petersen, C. et al. Stellungnahme. Strahlenther Onkol 174, 44–45 (1998). https://doi.org/10.1007/BF03038228
Issue Date:
DOI: https://doi.org/10.1007/BF03038228